Emblem Establishes Temporary “Patient Access Investment Fund” to Partially Cover Medical Cannabis Excise Tax
Emblem Corp. (TSXV:EMC, OTCQX:EMMBF) (“Emblem” or the “Company”) today announced that it will segregate CDN $5 million of its current cash holdings to establish what it is calling the Patient Access Investment Fund (the “Fund”), the interest from which will be used to help offset some of the cost of the excise tax that will be applied to medical cannabis products, effective October 17, 2018.
Federal and provincial governments to tax medical cannabis
On October 17, the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) will be replaced by the Cannabis Act, and all Licensed Producers will be required to collect and submit a federal cannabis excise tax to the government. The standard rate tax is the greater of $1.00/gram equivalent or 10% of the purchase price, with some provinces requiring an additional excise duty adjustment on top, which can range as high as 19.3% (the “New Excise Tax”).
In response to the New Excise Tax, Emblem will implement a $0.50/gram or equivalent increase to the prices of its medical cannabis products on October 17, 2018 and will absorb the remainder of the New Excise Tax over the $0.50 increase using interest from the Fund, with any portions not covered by the interest generated by the Fund being wholly absorbed by Emblem.
Patients are Emblem’s first priority
Emblem will continue to advocate against any tax on medicine and support organizations such as Canadians for Fair Access to Medical Marijuana (“CFAMM”) in their work to remove taxes from medical cannabis.
“Patients are our first and foremost priority and we stand together with them to advocate for the removal of taxes from medical cannabis. We believe that failing to do so will render this medicine less affordable, preventing vulnerable patients from accessing their physician-authorized medication,” said Nick Dean, CEO, Emblem Corp. “Until a time when the government decides to treat medical cannabis equitably to other medications, Emblem will cover the portion of the tax that is not covered through the retail prices changes on behalf of patients through the Patient Access Investment Fund.”
Cannabis already the only medicine subject to HST
“No other prescription medication in Canada is subject to tax. In fact, medical cannabis is already the only medicine subject to HST,” said James O’Hara, President and CEO of CFAMM. “The tax adds a significant financial burden to already-struggling patients and further marginalizes those managing a health condition. It increases the stigma that can come with using medical cannabis. Furthermore, it defeats the purpose behind the government’s often-stated position of driving purchases away from the black market.”
Another challenge for patients is that cannabis does not yet qualify for coverage by most private or government health insurance policies, so many patients are paying 100% out-of-pocket for their prescribed medication.
“Our message to patients is that we are all in this together. We are proud to support our patients during what we hope is only a temporary period of governments imposing an additional tax on medicine,” said Dean. “Canada needs the marketplace for medical cannabis to remain competitive to ensure adequate product choice for patients. A continued tax on medical cannabis is unsustainable in a competitive market, and in the end, patients will be hurt through reduced access to a wide variety of medicinal cannabis products. We encourage patients to join us in advocating to the federal government that medicine should not be taxed.”
About the Emblem Patient Access Investment Fund
The Fund is a CDN $5 million professionally-managed investment account, from which generated interest will be directed to covering the New Excise Tax applied to the Company’s medical cannabis products over the $0.50/gram equivalent that will be passed on to Emblem patients in the October 17, 2018 price update. The remaining portion of the New Excise Tax will be covered by Emblem, including any amounts required to be paid over and above the interest generated by the Fund.
Emblem is hopeful that the government will remove the excise tax on products sold to registered patients in the near future, at which time the Company will redirect the money in the Fund back into its working dollars, where it can be redeployed towards its primary intended purpose of supporting medical product development and innovation.
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
For investor inquiries, please contact:
Chief Financial Officer
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s December 31, 2017 Management’s Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.